诺贝尔生理学或医学奖得主巴里·马歇尔

寄语内容根据视频翻译整理：

女士们、先生们，我是巴里·马歇尔，西澳大利亚大学的教授，也是2005年生理学或医学领域的诺贝尔奖得主之一。我想对中国国家药品监督管理局以及虹桥国际经济论坛秘书处表示感谢，感谢他们邀请我今天在这里发表演讲。我将讨论关于全球药品安全、治理和中国的药品监管实践这一至关重要的话题。

我们的世界卫生格局目前正在经历迅速变革，主要原因是新冠疫情所带来的深远影响。当我们围绕药品安全和监管开启新的对话时，认识到药物固有的多面性特点也十分重要，这其中包括研究与开发药效、生产、分销、知识产权以及其他诸多方面。因此，当我们探讨健康与药物之间复杂的交集时，我们必须始终为潜在的突发情况做好准备，正如这次全球疫情给我们带来的警醒。与此同时，我们也不应忽视对传统医疗和药物生产进行现代化和创新的重要性。多年来，我的团队和我一直致力于在全球范围内（包括中国），研究与幽门螺杆菌有关的疾病以及各种相关领域。中国不仅拥有出类拔萃的人才，也具备利于科学进步的环境。这就是为什么我在多年前就决定与中国同事建立深入合作关系的原因。我很自豪地说，我们在深圳的合作项目诞生了这个领域最优质的医疗产品。

我希望我们在中国的工作成果将更好地满足中国民众和全球医疗市场的医疗保健需求，我热切期待与会者就全球卫生和医疗产品的现状分享富有洞见的看法和观察以及他们对未来的展望。此外，我期待着与各位共同探讨中国将如何加强医疗保健和药品监管体系以增进民生福祉，并为全球卫生领域做出贡献。

非常感谢大家！

视频寄语原文：

Ladies and gentlemen, I am Barry Marshall, a professor at the University of West Australia, and one of the Nobel Prize laureates in physiology or Medicine for the year 2005.

I wish to express my gratitude to the National Medical Products Administration of China and the Secretariat of the Hongqiao International Economic Forum for extending this invitation to address you today. I will be discussing the vital topic of global drug safety, governance and Chinese drug regulatory practices.

Our world’s health landscape is currently undergoing rapid transformation, primarily driven by the profound impact of the COVID-19 pandemic. While it is indeed personally to initiate new conversations centering around to drug safety and regulation, it is crucial to acknowledge the multifaceted nature of pharmaceuticals. They encompass various facets such as research and development, efficacy, production, distribution, intellectual property rights, and many others. Therefore, as we address the intricate intersection of health and pharmaceuticals, we must remain prepared for unforeseen emergencies such as the pandemic has undoubtedly reminded us. Simultaneously, we should not lose sight of the imperative to modernize and innovate traditional medical treatments and pharmaceutical productions. For several years, my team and I have dedicated our efforts to the study of Helicobacter pylori related diseases and various related areas on a global scale, including China. China boasts both exceptional talent and conducive environment for scientific advancement, this is why some years ago I made the decision to forge elaborative partnerships with Chinese colleagues, I'm proud to say that our joint venture in Shenzhen has yielded the finest medical products in the category.

My aspiration is that our work in China will better serve the healthcare needs of both the Chinese populace and the global medical markets, I eagerly anticipate the insightful perspectives and observations from fellow participants regarding the current state of global health and medical products along with their expectations. Furthermore, I look forward to exploring how China can enhance its healthcare and drug regulatory systems to optimize the well-being of its citizens and contribute to the global healthcare landscape.

Thank you very much！